Chugai Pharmaceutical Co., Ltd.
GPTKB entity
Statements (43)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Roche_acquired_a_majority_stake_in_2002
acquired_by_Roche_in_2002 |
| gptkbp:awards |
received multiple industry awards
|
| gptkbp:CEO |
Takahiro_Kiyoshi
|
| gptkbp:clinicalTrials |
conducts numerous clinical trials annually
collaborates with academic institutions focuses on innovative drug development conducts Phase I to Phase III trials has a strong pipeline of new drugs |
| gptkbp:corporateSocialResponsibility |
promotes diversity and inclusion in the workplace
engages in community health initiatives invests in employee development programs contributes to global health initiatives supports environmental sustainability programs |
| gptkbp:employees |
approximately 5,000
|
| gptkbp:founded |
1943
|
| gptkbp:founder |
gptkb:Kiyoshi_Chugai
|
| gptkbp:headCoach |
Dr._Masato_T._Nishikawa
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chugai Pharmaceutical Co., Ltd.
|
| gptkbp:market |
gptkb:Japan
|
| gptkbp:parentCompany |
gptkb:Roche
|
| gptkbp:partnerships |
partnered with Astellas
collaborates with various global pharmaceutical companies partnered_with_AbbVie partnered_with_Amgen partnered_with_Genentech partnered_with_Takeda |
| gptkbp:products |
antibody drugs
|
| gptkbp:research_areas |
neurology
cardiovascular diseases infectious diseases immunology |
| gptkbp:researchAndDevelopment |
focus on oncology
|
| gptkbp:revenue |
¥1.1 trillion (2020)
|
| gptkbp:specializesIn |
biopharmaceuticals
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:Chugai_Pharma_Europe
gptkb:Chugai_Pharma_Singapore gptkb:Chugai_Pharma_China gptkb:Chugai_Pharma_USA gptkb:Chugai_Pharma_Korea |